{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:39:30Z","timestamp":1792453170417,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["10104367"],"award-info":[{"award-number":["10104367"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-60295-2","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T23:15:12Z","timestamp":1784416512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Developability engineering of scFvs enables robust CAR function under transient mRNA expression"],"prefix":"10.1038","volume":"16","author":[{"given":"Maurizio","family":"Mangolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubin","family":"Ramon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Souster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder","family":"Hayre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Karattil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Sormanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimobi","family":"Onuoha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,19]]},"reference":[{"key":"60295_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1126\/science.3140379","volume":"242","author":"RE Bird","year":"1988","unstructured":"Bird, R. E. et al. Single-chain antigen-binding proteins. Science 242, 423\u2013426 (1988).","journal-title":"Science"},{"key":"60295_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","volume":"79","author":"Y Duan","year":"2022","unstructured":"Duan, Y. et al. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell. Mol. Life Sci. 79, 14 (2022).","journal-title":"Cell. Mol. Life Sci."},{"key":"60295_CR3","doi-asserted-by":"crossref","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, (2013).","DOI":"10.1126\/scitranslmed.3005930"},{"key":"60295_CR4","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"60295_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"60295_CR6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/2326-6066.CIR-23-0548","volume":"12","author":"M Fredon","year":"2024","unstructured":"Fredon, M. et al. Impact of scFv on functionality and safety of third-generation CD123 CAR T cells. Cancer Immunol. Res. 12, 1090\u20131107 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"60295_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman, J. et al. CAR-T design: Elements and their synergistic function. EBioMedicine 58, 102931 (2020).","journal-title":"EBioMedicine"},{"key":"60295_CR8","doi-asserted-by":"crossref","unstructured":"Bot, A. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat. Rev. Drug Discov. (2025).","DOI":"10.69645\/NEPO7828"},{"key":"60295_CR9","doi-asserted-by":"crossref","unstructured":"M. Mangolini et al. Highly potent novel multi-armoured IL13R$$\\alpha$$2 CAR-T subverts the immunosuppressive microenvironment of glioblastoma. Cancer Biol. (2025).","DOI":"10.1101\/2025.01.10.632392"},{"key":"60295_CR10","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"60295_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short, L., Holt, R. A., Cullis, P. R. & Evgin, L. Direct in vivo CAR T cell engineering. Trends Pharmacol. Sci. 45, 406\u2013418 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"60295_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.tips.2022.12.005","volume":"44","author":"J Kim","year":"2023","unstructured":"Kim, J. et al. Computational and artificial intelligence-based methods for antibody development. Trends Pharmacol. Sci. 44, 175\u2013189 (2023).","journal-title":"Trends Pharmacol. Sci."},{"key":"60295_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s42256-023-00778-3","volume":"6","author":"A Ramon","year":"2024","unstructured":"Ramon, A. et al. Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV. Nat. Mach. Intell. 6, 74\u201391 (2024).","journal-title":"Nat. Mach. Intell."},{"key":"60295_CR14","doi-asserted-by":"publisher","unstructured":"Aubin Ramon, Niccol\u00f2 Frassetto, Haowen Zhao, Xing Xu, Matthew Greenig, Shimobi Onuoha, and Pietro Sormanni. Deep learning assessment of nativeness and pairing likelihood for antibody and nanobody design with AbNatiV2. mAbs 18(1), 2646361. ISSN 1942-0862. https:\/\/doi.org\/10.1080\/19420862.2026.2646361 (2026).","DOI":"10.1080\/19420862.2026.2646361"},{"key":"60295_CR15","doi-asserted-by":"crossref","unstructured":"T.\u00a0Yin et al. Development of potent humanized TNF$$\\alpha$$ inhibitory nanobodies for therapeutic applications in TNF$$\\alpha$$-mediated diseases. mAbs 17 2498164. (2025).","DOI":"10.1080\/19420862.2025.2498164"},{"key":"60295_CR16","doi-asserted-by":"crossref","unstructured":"M.\u00a0Mangolini et al. Highly potent novel multi-armoured IL13R$$\\alpha$$2 CAR-T subverts the immunosuppressive microenvironment of glioblastoma. Cancer Biol. (2025).","DOI":"10.1101\/2025.01.10.632392"},{"key":"60295_CR17","doi-asserted-by":"crossref","unstructured":"T.\u00a0Yin et al. The NewroBus platform: engineered humanized anti-TfR1 nanobodies for efficient brain delivery. Cell Commun. Signal., (2025).","DOI":"10.1186\/s12964-025-02605-1"},{"key":"60295_CR18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/s42003-024-06561-3","volume":"7","author":"H Bashour","year":"2024","unstructured":"Bashour, H. et al. Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability. Commun. Biol. 7, 922 (2024).","journal-title":"Commun. Biol."},{"key":"60295_CR19","doi-asserted-by":"crossref","unstructured":"F.A. Harding, M.M. Stickler, J.\u00a0Razo, and R.B. DuBridge. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs 2, 256\u2013265, (2010).","DOI":"10.4161\/mabs.2.3.11641"},{"key":"60295_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s42003-023-04927-7","volume":"6","author":"B Abanades","year":"2023","unstructured":"Abanades, B. et al. ImmuneBuilder: Deep-learning models for predicting the structures of immune proteins. Commun. Biol. 6, 575 (2023).","journal-title":"Commun. Biol."},{"key":"60295_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","volume":"6","author":"SA Richman","year":"2018","unstructured":"Richman, S. A. et al. High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol. Res. 6, 36\u201346 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"60295_CR22","doi-asserted-by":"publisher","first-page":"2282250","DOI":"10.1080\/2162402X.2023.2282250","volume":"12","author":"H Wu","year":"2023","unstructured":"Wu, H. et al. A novel Fc-enhanced humanized monoclonal antibody targeting B7\u2013H3 suppresses the growth of ESCC. Oncoimmunology 12, 2282250 (2023).","journal-title":"Oncoimmunology"},{"key":"60295_CR23","doi-asserted-by":"publisher","first-page":"7196","DOI":"10.1038\/s41467-025-61427-4","volume":"16","author":"M Barisa","year":"2025","unstructured":"Barisa, M. et al. Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function. Nat. Commun. 16, 7196 (2025).","journal-title":"Nat. Commun."},{"key":"60295_CR24","doi-asserted-by":"crossref","unstructured":"H. Zola, P. J. MacArdle, T. Bradford, H. Weedon, H. Yasui, and Y. Kurosawa. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol. Cell Biol. 69 (Pt 6), 411\u2013422. ISSN 0818-9641 (1991).","DOI":"10.1038\/icb.1991.58"},{"key":"60295_CR25","unstructured":"K. Mujoo, T. J. Kipps, H. M. Yang, D. A. Cheresh, U. Wargalla, D. J. Sander, and R. A. Reisfeld. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 49 (11), 2857\u20132861. ISSN 0008-5472 (1989)."},{"key":"60295_CR26","doi-asserted-by":"crossref","unstructured":"Deryk Loo, Ralph F. Alderson, Francine Z. Chen, Ling Huang, Wenjun Zhang, Sergey Gorlatov, Steve Burke, Valentina Ciccarone, Hua Li, Yinhua Yang, Tom Son, Yan Chen, Ann N. Easton, Jonathan C. Li, Jill R. Rillema, Monica Licea, Claudia Fieger, Tony W. Liang, Jennie P. Mather, Scott Koenig, Stanford J. Stewart, Syd Johnson, Ezio Bonvini, and Paul A. Moore. Development of an Fc-enhanced anti-b7-h3 monoclonal antibody with potent antitumor activity. Clin. Cancer Res. 18 (14), 3834\u20133845. ISSN 1557-3265 (2012).","DOI":"10.1158\/1078-0432.CCR-12-0715"},{"key":"60295_CR27","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"60295_CR28","doi-asserted-by":"crossref","unstructured":"Ramon, A. Prediction of protein biophysical traits from limited data: a case study on nanobody thermostability through NanoMelt. mAbs 17, 2442750 (2025).","DOI":"10.1080\/19420862.2024.2442750"},{"key":"60295_CR29","doi-asserted-by":"crossref","unstructured":"P\u00e9rez, A.-M. Wolf. In vitro and in silico assessment of the developability of a designed monoclonal antibody library. mAbs 11, 388\u2013400 (2019).","DOI":"10.1080\/19420862.2018.1556082"},{"key":"60295_CR30","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1038\/s41467-023-37668-6","volume":"14","author":"A Rosace","year":"2023","unstructured":"Rosace, A. et al. Automated optimisation of solubility and conformational stability of antibodies and proteins. Nat. Commun. 14, 1937 (2023).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60295-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:40:30Z","timestamp":1792449630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60295-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60295"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60295-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,19]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Maurizio Mangolini, Emily Souster, Jasvinder Hayre, Rajesh Karattil and Shimobi Onuoha are current (or former) employees of Chimeris Ltd and receive (or received) salary and shares for their work. The contribution to this study of Pietro Sormanni and Aubin Ramon was conducted in a consultancy capacity and was remunerated by Chimeris UK.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Peripheral Blood Mononuclear Cells (PBMCs) were isolated from Leukocyte Reduction System (LRS) cones obtained from NHS Blood and Transplant (NHSBT), Cambridge, UK. The material was supplied as fully anonymised surplus clinical material under Human Tissue Authority (HTA) licence in accordance with the UK Human Tissue Act 2004. Donors provided consent for research use at the point of donation. All procedures were conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Large language model assistance (ChatGPT, OpenAI) was used for language editing and clarity improvement only. All scientific content and interpretations were reviewed and approved by the authors.","order":3,"name":"Ethics","label":"Use of large language models","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32891"}}